NEWS
14. May 2013
>Leading German online optician Mister Spex secures 16 million Euro investment to support international growth ...
7. March 2013
>immatics’ Mitgründer Professor Dr. Hans-Georg Rammensee erhält den Familie-Hansen-Preis 2013 Familie-Hansen-Preis als Anerkennung für ...
29. January 2013
>Expand Oncology Antibody R&D Program with Three New Targets 4-Antibody AG and the Ludwig ...
24. January 2013
>Starkes Wachstum: Online-Optiker Mister Spex erreicht 26 Mio. Euro Jahresumsatz Vertrauen in Online-Brillenkauf und Marke ...
4. December 2012
>Zwei Tage, die über Erfolg und Misserfolg entscheiden Von Tobias Bauckhage Hollywoods Marketing-Strategen stehen ...
8. November 2012
>immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment and is granted US orphan ...
17. October 2012
>Mister Spex erweitert Logistikzentrum und schafft Arbeitsplätze am Standort Berlin Marktführender Online-Optiker bezieht ...
16. October 2012
>'Love at First Touch': URBANARA eröffnet Pop Up Shop in Berlin URBANARA, die Online-Marke ...
12. July 2012
>mysportgroup enters the e-commerce heavy weight division Award-winning mysportgroup raised €13.5m in its Series ...
1. June 2012
>immatics presents encouraging overall survival data from a phase 2 study in Advanced Colorectal Cancer ...
25. May 2012
>immatics wins 2012 TiE50 Award immatics chosen as a leading company in the life ...
14. May 2012
>Starboard Storage Systems Closes $13 Million Series B Round of Funding Accelerates Market Momentum ...
10. May 2012
>MoviePilot Seals $7M Series B Funding Led By DFJ Esprit It’s easy to miss ...
17. April 2012
>Quantenna Communications Raises $79 Million Led by RUSNANO and Sequoia Capital Oversubscribed Funding Round ...
17. April 2012
>Online-Optiker Mister Spex expandiert nach Skandinavien - Berliner E-Commerce-Unternehmen launcht schwedischen Online-Shop für Kontaktlinsen, Brillen ...
12. April 2012
>immatics appoints Dr Rainer Kramer as Chief Business Officer immatics biotechnologies GmbH, a clinical-stage ...
4. April 2012
>Starboard Storage Systems and Acronis Bring Optimized Storage Solutions to Small and Medium Enterprises ...
29. March 2012
>Geschäftspläne von HHL-Studenten in Medizin und E-Commerce erfolgreich Businesspläne zur Einführung eines Arzneimittels zur Behandlung ...
28. March 2012
>Promark Technologies to Offer Starboard Storage Systems Industry Leading Margins for Resellers, New Starboard ...
20. March 2012
>Large Binocular Telescope Observatory Looks to the Stars with Purchase of Starboard Storage AC72 ...
13. February 2012
>Starboard Storage Systems™ Announces AC72 to Address Small and Medium Enterprise Need for Mixed Workload ...
13. February 2012
>A team of storage industry leaders from Compellent, HP, LeftHand Networks, LSI and Sun today ...
1. February 2012
>Deutschlands größter Online-Händler für Markenbrillen gehört zu Top-Ten-Unternehmen der Optikbranche Der Online-Optiker Mister Spex ...
31. January 2012
>XConnect and IPV Collaborate to Reduce Cost, Complexity of Video Calling and Conferencing ...
24. January 2012
>immatics presents positive Phase II results with its therapeutic cancer vaccine IMA910 in patients with ...
5. December 2011
>With a Click of the Remote, Impulse Purchases Giving television viewers the ability to ...
22. November 2011
>Berliner Online-Optiker erhält Auszeichnung im Rahmen von „125 Jahre Versandhandel“ bei Insight E-Commerce in Leipzig ...
7. November 2011
>TELEFÓNICA MAKES STRATEGIC INVESTMENT IN QUANTENNA Telefónica Digital through its Venture Capital arm joins other ...
3. November 2011
>mysportgroup (Privatesportsale GmbH), Betreiberin der eCommerce-Angebote www.mysportbrands.de und www.mysportworld.de, konnte eine signifikante Finanzierungsrunde zur Fortsetzung ...
2. November 2011
>Delivery Agent Raises $35.5 Million Led by Intel Capital with Liberty Global, and Grazia Equity ...
19. September 2011
>4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration 4-Antibody AG today announced the ...
16. September 2011
>Mister Spex (www.misterspex.de) erhält Gütesiegel „EHI Geprüfter Online-Shop“ und baut 3D-Anprobe aus Das EHI-Gütesiegel ...
12. September 2011
>Das Hamburger Statistikportal Statista expandiert in die USA und eröffnet eine Niederlassung in New York ...
1. September 2011
>Ehemaliger Metaversum-Mitgründer Mirko Caspar neu als Geschäftsführer für Marketing und Vertrieb beim größten deutschen Online-Shop ...
24. August 2011
>“150 Leute, 35 Grad und 80 % Luftfeuchtigkeit – das macht Spaß!” Benjamin Esser von ...
22. August 2011
>Berliner Online-Brillenhändler startet deutschlandweites Partnernetzwerk mit lokalen Augenoptikern Als erster deutscher Online-Brillenshop kooperiert Mister ...
16. August 2011
>AirTies Partners with Quantenna to Deliver Wireless HD Video Streaming with Unparalleled Range and Performance ...
3. August 2011
>Leader in Ultra-Reliable 802.11n Wi-Fi Home Video Networking is Lauded for Third Consecutive Year ...
11. July 2011
>Finanzspritze für Urbanara - Online-Shop sammelt siebenstellige Summe ein “Qualitativ hochwertige Heimtextilien und Wohnaccessoires” ...
29. June 2011
>XConnect Vice President John Wilkinson Honored by Global Telecoms Business for Second Consecutive Year ...
20. June 2011
>Online-Anprobe von Brillen im Internetshop erstmals in 3D möglich Versandhändler Mister Spex geht als erster ...
24. May 2011
>4-Antibody AG Forms Multi-target Oncology Research and Development Alliance with the Ludwig Institute 4-Antibody ...
23. May 2011
>Mister Spex zählt zu schnellstwachsenden Internetunternehmen Europas Berliner Online-Optiker belegt bei GP Bullhound Media ...
19. May 2011
>B2X Care Solutions launches in North America After-sales services provider B2X Care Solutions (http://www.b2xcare.com) ...
12. May 2011
>Mister Spex rockt im TV - Der neue Sonnenbrillenspot geht heute on air Der ...
11. May 2011
>Adconion Media Group Completes Multi-Million Dollar Financing with Silicon Valley Bank Adconion Media Group, ...
11. April 2011
>immatics to receive support from Pfizer for its pivotal Phase III study (IMPRINT) with IMA901, ...
6. April 2011
>New Industry Research Confirms RELDATA Is Positioned to Continue Significant Growth Key Findings from Storage ...
31. March 2011
>http://www.gruenderszene.de Interview mit einem VC: Grazia – Jochen Klüppel im Gespräch Sie sind ...
28. March 2011
>Online-Brillenhändler startet Partnerprogramm mit stationären Optikern, um Service für die Kunden weiter zu verbessern ...
4. February 2011
>Berliner Online-Brillenhändler in Brüssel von Gerhard Schröder als eines der wachstumsstärksten Unternehmen ausgezeichnet Mister ...
2. February 2011
>Berliner Online-Brillenhändler erzielt im Jahr 2010 rund 11 Millionen Euro Umsatz Drei Jahre nach ...
31. January 2011
>RELDATA Inc. (www.RELDATA.com), the innovation leader in unified block and file storage solutions over iSCSI, ...
11. January 2011
>RELDATA Secure $4 M in Series B for Innovative Data Storage Solution RELDATA, a ...
5. January 2011
>Quantenna Features Award-Winning 4x4 MIMO 802.11n Wi-Fi Home Networking Technology at CES 2011 Winning ...
29. October 2010
>Mister Spex siegt beim Deutschen Unternehmer Preis 2010 Online-Brillenhändler überzeugt in der Kategorie Startup ...
19. October 2010
>Verlagsgruppe Handelsblatt baut mit Statista Paid-Content-Bereich aus Die Verlagsgruppe will Entscheiderm zukünftig mehr ...
21. September 2010
>immatics raises €54 million to advance its late stage clinical therapeutic cancer vaccine portfolio ...
10. September 2010
>Über 7 Mio. Euro für Mister Spex Mister Spex, Deutschlands größter Online-Versandhändler für Markenbrillen ...
12. July 2010
>RELDATA Named Tech Awards Circle Winner / Unified Block and File Storage Solutions Provider Selected ...
18. June 2010
>RELDATA Selected as AlwaysOn East Top 100 Winner for Cloud and Infrastructure Technology Unified Storage ...
7. June 2010
>On June 24, 2010, the 8th annual Grazia Equity Business Plan Competition was hosted at ...
5. June 2010
>immatics announces Phase II Results with its Therapeutic Cancer Vaccine IMA901 in Patients with Advanced ...
2. June 2010
>Online-Brillenhändler Mister Spex zählt zu "Red Herring 100 Europe" Unternehmen Red Herring Europe Award ...
2. June 2010
>immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 ...
16. February 2010
>immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine ...
4. February 2010
>XConnect revenue doubled in 2009 XConnect, the leader in next-generation interconnection and carrier ENUM-registry ...
1. February 2010
>Online-Brillenhändler Mister Spex hat 2009 Brillen und Kontaktlinsen für rund 4,5 Millionen Euro verkauft – ...
26. January 2010
>RELDATA UNIFIED STORAGE NAMED ONE OF “100 COOLEST CLOUD COMPUTING PRODUCTS” BY EVERYTHING CHANNEL’S CRN ...
20. January 2010
>RELDATA (www.reldata.com), a provider of software-centric unified storage solutions, announced today its new RELDATA Partner ...
14. January 2010
>HORIZONT und Statista starten Portal HORIZONTstats.de Premium-Initiative für Paid Content Auf HORIZONTstats.de gibt es ...
9. December 2009
>First Chip Supplier to Offer 4x4 MIMO Wi-Fi Devices Will Play Active Role in One ...
2. December 2009
>Conergy Solar Factory in Frankfurt (Oder): Three Years "Quality Made in Germany" Ramp ...
20. November 2009
>Investoren-Einstieg unterstützt weitere Wachstumsstrategie Der Stuttgarter Finanzinvestor Grazia Equity ist beim After Sales Dienstleister ...
16. November 2009
>Allzu viele Partner bei der Finanzierung können das Wachstum eines jungen Unternehmens stören. Es kommt ...
19. October 2009
>Mit Mister Spex bringt Dirk Graber den Durchblick zurück. Wir haben ihn zu seiner Arbeit ...
5. October 2009
>Statistik-Portal startet heute sein Premium-Angebot, das für 29,90 Euro pro Monat die Verwendung exklusiver Daten ...
1. October 2009
>"Gründerszene ist sehr unterentwickelt" Von Claus G. Schmalholz Lothar Späth, zuletzt Vorsitzender der ...
29. September 2009
>immatics biotechnologies GmbH today announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer ...
22. September 2009
>RELDATA Introduces Next Generation 9240i Unified Storage System Powered by Enhanced RELvos 2.4 Virtualization OS ...
16. September 2009
>Venture capital firms Venrock Associates, Accel Partners, Grazia Equity and Crescent Point Group all participated ...
9. September 2009
>Nanosolar Completes Panel Factory, Commences Serial Production Today Nanosolar demonstrated the completion of its ...
9. September 2009
>Nanosolar Unveils Nanosolar Utility Panel™ Technology In conjunction with today's inauguration of our panel-assembly ...
9. September 2009
>NREL Certifies 16.4% Nanosolar Foil Efficiency It was May 2006 when we last released ...
10. August 2009
>immatics biotechnologies GmbH today announced that the company obtained European patent protection for the composition ...
27. July 2009
>Portal will Informationen für Marketingentscheider bündeln Mit einem neuen Seitenkonzept will das Statistik-Portal „Statista“ ...
21. July 2009
>RELDATA Named a CRN Emerging Technology Vendor RELDATA's unified storage solutions provide channel partners ...
7. July 2009
>Ehemaliger Ministerpräsident arbeitet für Venture Capital-Geber: Lothar Späth berät Grazia Equity Prof. Dr. h.c. ...
3. July 2009
>Grazia Equity Award für die beste Geschäftsidee an der HHL Von einer Charityplattform ...
30. June 2009
>Conergy sells solar portfolio with a capacity of 10.7 MWp ...
17. June 2009
>immatics biotechnologies significantly improves XPRESIDENT™ technology platform. immatics biotechnologies today announced the completion of ...
10. June 2009
>Australia: Planning Approval for 282 Wind Turbines EPURON reaches key milestone for the largest ...
8. June 2009
>Conergy Deutschland GmbH sells the Heimpersdorf megawatt solar park to investor Conergy Deutschland GmbH ...
29. May 2009
>moviepilot.de: Führender personalisierbarer Entertainmentguide für Kino, DVD und TV schließt zweite Finanzierungsrunde ab Berlin, 29.05.2009 ...
19. May 2009
>Solarstrom von Conergy reduziert Kosten für Wasserversorgung in Kalifornien • 1,6 MWp Solarpark im ...
14. May 2009
>Statista startet Geschäftskunden-Angebot Statistik-Portal bietet umfassende Markenreports und kostengünstige Online-Umfragen Ausführliche Analysen zu ...
12. May 2009
>Quantenna Communications Names David French as New CEO Founder Behrooz Rezvani Continues with Company ...
8. May 2009
>Solar energy from the region, for the region: Conergy Deutschland inaugurates a megawatt class thin-film ...
8. May 2009
>Solar energy from the region, for the region: Conergy Deutschland inaugurates a megawatt class thin-film ...
28. April 2009
>XCONNECT NAMES RICHARD SHOCKEY, ENUM PIONEER AND IP COMMUNICATIONS EXPERT, TO ADVISORY BOARD Appointment ...
27. April 2009
>RELDATA EXPANDS ITS SALES ORGANIZATION Industry Veteran Peter Cmaylo joins RELDATA as VP Sales ...
22. April 2009
>XCONNECT EXPANDS GLOBAL ALLIANCE FEDERATION SERVICES Innovations Bring Communications Service Providers More NGN ...
21. April 2009
>XCONNECT RECEIVES 2009 NGN LEADERSHIP AWARD FROM NGN MAGAZINE Global Alliance Honored for Outstanding ...
20. April 2009
>Must-have-Accessoires: Hält die Brille mit der It-Bag Schritt? Das Mister Spex "Brillen-Mode-Barometer" analysiert ...
8. April 2009
>Metaversum and Twinity has been elected a Red Herring 100 Europe Winner 2009 With ...
24. March 2009
>OVERGENCE SESSION MANAGER LATEST VOIP-PEERABLE DEVICE CERTIFIED XCONNECT-READY Testing for ENUM Query Compatibility Streamlines ...
11. March 2009
>NETNUMBER TITAN SERVER CERTIFIED XCONNECT-READY, SIMPLIFYING VOIP FEDERATION-BASED INTERCONNECTION Interoperability Testing Streamlines ...
2. March 2009
>immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell ...
24. February 2009
>Quantenna Raises $15 Million in Series D Financing Round Quantenna Communications, Inc., a leader ...
24. February 2009
>RELDATA AND XYRATEX ENABLE HETEROGENEOUS STORAGE RELDATA 9240 and Xyratex F6412E RAID system certification ...
26. January 2009
>immatics wins 29th German Industry’s Innovation Award (Innovationspreis der deutschen Wirtschaft) Tuebingen, January 26, ...
26. January 2009
>The Growing Market for Solar Cells Printing is playing a key role in ...
26. January 2009
>SMC Networks Announces 10G Certification with RELDATA’s Unified iSCSI Storage System to Enable High-Performance Virtualized ...
24. January 2009
>VC Investing Drops For 2008, But Green Grows Venture capital investment shrank in 2008 ...
21. January 2009
>Feeding In Renewable Energy Breakthroughs What renewable energy really needs is a shift to ...
5. September 2008
>Wowereit Opens Virtual Berlin in Twinity Metaversum GmbH, developer and operator of the ...
27. August 2008
>Nanosolar outshines the competition with a $ 300M financing Chris Morrison Thin-film solar ...
11. April 2011
immatics: Phase III study
immatics to receive support from Pfizer for its pivotal Phase III study (IMPRINT) with IMA901, a therapeutic vaccine for advanced renal cell cancer patients
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT = IMA901 Multi-Peptide vaccine Randomized INTernational study) with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.
The pivotal Phase III study will evaluate as the primary endpoint the overall survival of advanced renal cell carcinoma patients treated with IMA901 in combination with Pfizer’s Sutent® (sunitinib malate) versus Sutent® alone. The study is expected to enroll approximately 330 patients across Europe and in the US.
Pfizer will support the trial by supplying Sutent® for all the patients enrolled in the pivotal study. The first patients are expected to start treatment in April 2011.
Paul Higham, CEO of immatics, said: “We are extremely pleased that Pfizer has committed to supporting our pivotal Phase III trial with IMA901 with the supply of Sutent. Their decision reflects the growing interest in IMA901 and its potential to be an important breakthrough in the treatment of renal cell carcinoma patients.”
IMA901 has generated encouraging overall survival data, which compare favorably with historical comparisons of currently available treatments, in a Phase II trial in advanced renal cell carcinoma patients. Importantly, the Phase II study also showed an association between survival and the patient’s immune response to IMA901, as well as confirming the favorable safety profile observed in an earlier Phase I study.
“Pfizer is pleased to provide Sutent to support immatic’s clinical development program in advanced renal cell carcinoma patients,” said Craig Eagle, Vice President of Strategic Alliances and Partnerships for Pfizer Oncology. “This collaboration underscores Pfizer’s ongoing commitment to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.”
For additional information on immatics please visit www.immatics.com or contact:
Paul Higham, CEO
Katrin Eckert, Assistant to the Management
immatics biotechnologies GmbH
Phone: +49-7071-5397-110
E-mail: media@immatics.com
David Dible / Chris Gardner / Sita Shah
Citigate Dewe Rogerson
Phone: +44 207 638 9571
E-mail: david.dible@citigatedr.co.uk
For more information on SUTENT and Pfizer please visit www.pfizer.com.
About IMA901
IMA901 is a therapeutic cancer vaccine comprising 10 tumor-associated peptides (TUMAPs) that are frequently found to be over-expressed in the majority of patients suffering from renal cell carcinoma. As with all immatics’ vaccines, IMA901 has been designed to elicit a strong, clinically relevant immune response to a specific tumor type. The TUMAPs were selected from over 2,000 peptides identified via immatics’ unique XPRESIDENT™ platform. TUMAPs included in IMA901 are from targets with vital functions for the tumor, for example invasion, neo-angiogenesis.
About SUTENT(®) (sunitinib malate)
SUTENT is an oral multi-kinase inhibitor approved for the treatment of advanced/metastatic renal cell carcinoma (RCC), unresectable and/or metastatic malignant gastrointestinal stromal tumor (GIST) after failure of imatinib mesilate treatment due to resistance or intolerance.
In Europe, SUTENT is also indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. Experience with SUTENT as first-line treatment is limited.
SUTENT works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer. Two important SUTENT targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), are expressed by many types of solid tumors and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth. SUTENT also inhibits other targets important to tumor growth, including KIT, FLT3 and RET.
Important SUTENT(®) (sunitinib malate) Safety Information
Hepatotoxicity has been observed in clinical trials and post-marketing experience. Cases of hepatic failure, some with a fatal outcome, were observed in <1% of solid tumor patients treated with SUTENT. It is recommended to monitor liver function tests before initiation of treatment, during each cycle of treatment, and as clinically indicated. If signs or symptoms of hepatic failure are present, sunitinib should be discontinued and appropriate supportive care should be provided.
Women of child bearing age who are (or become) pregnant during therapy should be informed of the potential for fetal harm while on SUTENT.
Decreases in left ventricular ejection fraction (LVEF) to below the lower limit of normal (LLN) have been observed. Patients with concomitant cardiac conditions should be carefully monitored for clinical signs and symptoms of congestive heart failure. Patients should be monitored for hypertension and treated as needed with standard antihypertensive therapy. Complete blood counts (CBCs) with platelet count and serum chemistries should be performed at the beginning of each treatment cycle for patients receiving treatment with SUTENT.
The most common adverse reactions in GIST, RCC and pancreatic NET clinical trials were diarrhea, fatigue, asthenia, nausea, mucositis/stomatitis, anorexia, vomiting, neutropenia, hypertension, dyspepsia, abdominal pain, constipation, rash, hand-foot syndrome, skin discoloration, hair color changes, altered taste and bleeding. For more information on SUTENT and Pfizer Oncology, including full prescribing information for SUTENT (sunitinib malate), please visit www.pfizer.com.
About immatics
immatics biotechnologies is a clinical-stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer. immatics’ lead product, IMA901, has completed a successful phase II trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, in phase II for colorectal cancer, and IMA950 which is in phase I for glioma.
immatics’ XPRESIDENT™ technology platform rapidly generates defined therapeutic cancer vaccines, based on multiple tumor-associated peptides (TUMAPs), that have the ability to specifically stimulate the immune system against cancer cells. These vaccines – comprising multiple peptides confirmed to be naturally presented by real tumor tissue – offer the prospect of greater effectiveness than existing cancer vaccine approaches. immatics’ products are ‘drug like’ with stable, off-the-shelf formulations and robust easily scalable manufacturing.
immatics is based in Tuebingen and Munich, Germany.